Study of a new drug for cancer-related weight loss
Part of Cancer clinical trials.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have cancer-related weight loss and muscle wasting (cachexia) confirmed by your doctor.
- You must be able to get around and take care of yourself (ECOG status 0 or 1).
- You cannot be on tube feedings or IV nutrition for the past month.
- Your weight loss must not be caused by another illness or a feeding problem.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called GFS202A for people with advanced solid tumors who are experiencing weight loss or have a low body mass index (cachexia). The goal is to see if the drug is safe and can help improve appetite and weight.
This study tests an investigational drug called INB301 to see if it can help cancer patients who have lost significant weight due to their disease. The drug targets a protein involved in appetite and muscle loss.
This study tests a new medicine called DS010 to help patients with cancer cachexia—severe weight loss and muscle wasting caused by cancer. Researchers want to see if this treatment is safe and helps patients maintain weight and strength.
This trial tests a new drug, ASCA101, for people with certain cancers who are experiencing unwanted weight loss (cachexia). It aims to see if the drug can help improve appetite and stabilize weight. Participants must have colorectal, ovarian, or lung cancer and meet specific weight loss criteria.
This trial tests a new appetite-boosting medicine (nano-crystalline megestrol acetate) added to standard chemotherapy for people with advanced small cell lung cancer who are losing weight. It aims to see if it helps with weight, strength, and treatment response.
This Phase 1 trial tests a new drug (AV-380) in people with solid tumor cancer who are losing weight and muscle because of cancer. It mainly helps researchers find a safe dose and see how the body responds, and it may offer a new option for cancer-related cachexia.
Hear when a new Cancer Cachexia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.